Thomas Catinazzo - 13 Sep 2021 Form 4 Insider Report for Relay Therapeutics, Inc. (RLAY)

Role: Senior Vice President, Finance
Signature: /s/ Brian Adams, as Attorney-in-Fact
Issuer symbol: RLAY
Transactions as of: 13 Sep 2021
Net transactions value: -$694,800
Form type: 4
Filing time: 13 Sep 2021, 20:24:31 UTC
Previous filing: 30 Jun 2021
Next filing: 27 Sep 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RLAY	Common Stock	Options Exercise	$92,700	+22,500	+144%	$4.12	38,077	13 Sep 2021	Direct	F1
transaction	RLAY	Common Stock	Sale	$787,500	-22,500	-59%	$35.00	15,577	13 Sep 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RLAY	Stock Option (Right to Buy)	Options Exercise	$0	-22,500	-27%	$0.000000	62,043	13 Sep 2021	Common Stock	22,500	$4.12	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 17, 2020.
F2	Twenty-five percent (25%) of the shares underlying this option vested on April 9, 2019 and the remainder shall vest in equal quarterly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date.